60 Degrees Pharmaceuticals Inc. Common Stock (SXTP)
Stock · NASDAQ · Health Care
$0.8554as of 10/16/2026
Price chart
Active signals
SXTP Signal Track Record
How signals performed across all stocks →What SXTP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 20 | -24.6% | 25% | September 29, 2026 |
| Bollinger Band Breakdown | 12 | -11.8% | 42% | September 2, 2026 |
| Bollinger Band Breakout | 10 | -10.2% | 20% | September 23, 2026 |
| Any 20-session window (baseline) | -13.1% | 33% |
Computed by MarketWall from daily closing prices since April 25, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SXTP
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3
- Website
- 60degreespharma.com/
Fundamentals
- 1-day range
- $0.85$0.912
- Market cap
- $3.28M
- P/E (trailing)
- —
- P/E (forward)
- -0.24
- EPS (trailing)
- $-5.93
- Dividend yield
- —
- Beta
- 2.38
- Avg. volume
- 132.7K
How 60 Degrees Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 30, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
60 Degrees Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SXTP60 Degrees Pharmaceuticals Inc. Common Stock$0.855▼ 4.89%Market cap $3.28MP/E —$0.835$8.62
- ONCOOnconetix Inc. Common Stock$0.479▼ 12.59%Market cap $3.34MP/E 0.00$0.535$200
- PRFXPRF Technologies Ltd. Ordinary Shares$0.781▼ 7.68%Market cap $3.35MP/E —$0.8099$7.95
- XRTXXORTX Therapeutics Inc. Common Shares$1.24▼ 12.68%Market cap $3.51MP/E —$2.42$9.85
- RDHLRedhill Biopharma Ltd. American Depositary Shares$0.48▼ 3.81%Market cap $3.53MP/E Infinity$0.4351$2.14
- SBFMSunshine Biopharma Inc. Common Stock$0.222▼ 3.48%Market cap $2.97MP/E —$0.4117$24.3
- SHPHShuttle Pharmaceuticals Holdings Inc. Common Stock$5.08▼ 8.80%Market cap $2.79MP/E 43.60$2.58$55.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SXTP 60 Degrees Pharmaceuticals Inc. Common Stock | $3.28M | — | $0.855 | ▼ 4.89% | $0.835$8.62 |
| ONCO Onconetix Inc. Common Stock | $3.34M | 0.00 | $0.479 | ▼ 12.59% | $0.535$200 |
| PRFX PRF Technologies Ltd. Ordinary Shares | $3.35M | — | $0.781 | ▼ 7.68% | $0.8099$7.95 |
| XRTX XORTX Therapeutics Inc. Common Shares | $3.51M | — | $1.24 | ▼ 12.68% | $2.42$9.85 |
| RDHL Redhill Biopharma Ltd. American Depositary Shares | $3.53M | Infinity | $0.48 | ▼ 3.81% | $0.4351$2.14 |
| SBFM Sunshine Biopharma Inc. Common Stock | $2.97M | — | $0.222 | ▼ 3.48% | $0.4117$24.3 |
| SHPH Shuttle Pharmaceuticals Holdings Inc. Common Stock | $2.79M | 43.60 | $5.08 | ▼ 8.80% | $2.58$55.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA MeetingYahoo · 10/6/2026
- There are notable gap-ups and gap-downs in today's session.ChartMill · 10/6/2026
- 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDAYahoo · 10/6/2026
- 60 Degrees Pharmaceuticals Will Conclude Enrollment In Study Of Tafenoquine In Patients Hospitalized With Severe Babesiosis And Proceed With Unblinding; Primary And Secondary Endpoint Results Are Expected In January 2027Benzinga · 10/6/2026
- 60 Degrees Pharmaceuticals Stock Falls 6% in Pre-Market Ahead of Tafenoquine Trial Interim Results: What Investors Are Watching Tuesday?Benzinga · 10/6/2026
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga · 10/5/2026
- 60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVYahoo · 10/2/2026
- 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader WebinarYahoo · 10/1/2026
Insider Activity
Insider Actions →- DOW GEOFFREY S · June 12, 2026 · Buy7.3K @ $1.38
Institutional Ownership
March 31, 2026
- Total shares held
- 194.3K
- Total value held
- $340.0K
- Institutional holders
- 7
- Unknown144.7K
- Unknown31.4K
- Unknown16.3K
- Unknown1.9K
- Unknown25
- Unknown8
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
SXTP to Release Babesiosis Interim Data and Appear on CNBC
60 Degrees Pharmaceuticals will share interim results from its hospitalized babesiosis study and host a key‑opinion‑leader webinar later this month. The company will also discuss the data on the RedChip Small Stocks, Big Money show broadcast on CNBC and Bloomberg TV. A separate presentation of tafenoquine trial analysis is scheduled for Oct. 6. These events raise the profile of the company's clinical program.
SXTP to Release Babesiosis Interim Data and Appear on CNBC. 60 Degrees Pharmaceuticals will share interim results from its hospitalized babesiosis study and host a key‑opinion‑leader webinar later this month. The company will also discuss the data on the RedChip Small Stocks, Big Money show broadcast on CNBC and Bloomberg TV. A separate presentation of tafenoquine trial analysis is scheduled for Oct. 6. These events raise the profile of the company's clinical program.